{"transactions":[{"id":739574,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:00:59.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":70000,"derivative":{"exercise_price":1.14,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001746473-26-000100","document":"wk-form4_1781298056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000174647326000100/wk-form4_1781298056.xml","form_type":"4"}},{"id":963054,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":3093293,"price":0.4041,"value":1249999.7013,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":3093293,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":3093293},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":963053,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":3093293,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 3,093,293 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 3,219,160 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":3093293,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":3093293},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":963052,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"price":0.4041,"value":249999.6978,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":963051,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-18T21:57:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028420","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000149315225028420/ownership.xml","form_type":"4"}},{"id":1117740,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-09T20:43:08.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000125","document":"wk-form4_1749516175.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000174647325000125/wk-form4_1749516175.xml","form_type":"4"}},{"id":1193309,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T17:00:10.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025043936/ownership.xml","form_type":"4"}},{"id":1193308,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T17:00:10.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025043936/ownership.xml","form_type":"4"}},{"id":1214894,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T17:00:16.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":892857,"price":1.12,"value":999999.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":892857,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":892857},"source":{"system":"sec-edgar","filing":"0000950170-25-036488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025036488/ownership.xml","form_type":"4"}},{"id":1214893,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T17:00:16.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":892857,"price":1.12,"value":999999.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":892857,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":892857},"source":{"system":"sec-edgar","filing":"0000950170-25-036488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025036488/ownership.xml","form_type":"4"}},{"id":1214892,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T17:00:16.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":892857,"price":1.12,"value":999999.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 892,857 ADS  and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":4695854,"source":{"system":"sec-edgar","filing":"0000950170-25-036488","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017025036488/ownership.xml","form_type":"4"}},{"id":1361609,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-18T18:53:40.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F6","text":"At the Effective Time, each option to purchase shares of Peak Common Stock (\"Peak Option\") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an \"Assumed Option\") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"At the Effective Time, each option to purchase shares of Peak Common Stock (\"Peak Option\") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an \"Assumed Option\") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"At the Effective Time, each option to purchase shares of Peak Common Stock (\"Peak Option\") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an \"Assumed Option\") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":0.8,"underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000950170-24-128149","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017024128149/ownership.xml","form_type":"4"}},{"id":1361608,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Purchase)","published_at":"2024-11-18T18:53:40.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":176292,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F5","text":"At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a \"Peak Warrant\") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the \"Assumed Warrants\"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a \"Peak Warrant\") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the \"Assumed Warrants\"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a \"Peak Warrant\") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the \"Assumed Warrants\"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"At the Effective Time, each warrant to purchase capital stock of the Issuer (each, a \"Peak Warrant\") outstanding immediately prior to the Effective Time was converted into warrants to purchase a number of Ordinary Shares or ADSs (the \"Assumed Warrants\"), exercisable for a number of ADSs equal to the number of shares of Peak Common Stock underlying such Peak Warrant multiplied by the Exchange Ratio, and the exercise price with respect to such Assumed Warrants shall be equal to the exercise price of such Peak Warrant divided by the Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":0.6,"underlying":"Common Stock","underlying_shares":176292},"source":{"system":"sec-edgar","filing":"0000950170-24-128149","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017024128149/ownership.xml","form_type":"4"}},{"id":1361607,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2024-11-18T18:53:40.000Z","date":"2024-11-14","kind":"exercise","planned":false,"acquired":false,"reported_value":2130775,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4574661},"source":{"system":"sec-edgar","filing":"0000950170-24-128149","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017024128149/ownership.xml","form_type":"4"}},{"id":1361606,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T18:53:40.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":372940,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Hannol Ventures LLC. The Reporting Person is sole member of the LLC."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-128149","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017024128149/ownership.xml","form_type":"4"}},{"id":1361605,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T18:53:40.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8382742,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-128149","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017024128149/ownership.xml","form_type":"4"}},{"id":1361604,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T18:53:40.000Z","date":"2024-11-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4574661,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") American Depositary Shares (\"ADSs\") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the \"Ordinary Shares\") of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-128149","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017024128149/ownership.xml","form_type":"4"}},{"id":1361603,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T18:53:40.000Z","date":"2024-11-14","kind":"exercise","planned":false,"acquired":true,"shares":4574661,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the \"Merger Agreement\"), by and among the Issuer, Akari Therapeutics Plc (\"Parent\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the effective time of the Merger (the \"Effective Time\"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer (\"Peak Common Stock\")."}],"balance_after":4574661,"source":{"system":"sec-edgar","filing":"0000950170-24-128149","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017024128149/ownership.xml","form_type":"4"}},{"id":1477150,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-17T20:16:17.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":26764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":26764,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":26764},"source":{"system":"sec-edgar","filing":"0001746473-24-000106","document":"wk-form4_1718669767.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000174647324000106/wk-form4_1718669767.xml","form_type":"4"}},{"id":1773887,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-25T16:05:03.000Z","date":"2023-09-21","kind":"purchase","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2023, Dr. Hoyoung Huh purchased a total of 45,000 shares of the Company's Common Stock at prices ranging from $0.19 per share to $0.21 per share."}],"balance_after":8382742,"source":{"system":"sec-edgar","filing":"0000950170-23-049688","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023049688/ownership.xml","form_type":"4"}},{"id":1775334,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T16:05:05.000Z","date":"2023-09-20","kind":"purchase","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 20, 2023, Dr. Hoyoung Huh purchased a total of 30,000 shares of the Company's Common Stock at prices ranging from $0.19 per share to $0.21 per share."}],"balance_after":8337742,"source":{"system":"sec-edgar","filing":"0000950170-23-049173","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023049173/ownership.xml","form_type":"4"}},{"id":1775333,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-21T16:05:05.000Z","date":"2023-09-19","kind":"purchase","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 19, 2023, Dr. Hoyoung Huh purchased a total of 50,000 shares of the Company's Common Stock at prices ranging from $0.207 per share to $0.22 per share."}],"balance_after":8307742,"source":{"system":"sec-edgar","filing":"0000950170-23-049173","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023049173/ownership.xml","form_type":"4"}},{"id":1777189,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-19T16:05:08.000Z","date":"2023-09-15","kind":"purchase","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 15, 2023, Dr. Hoyoung Huh purchased a total of 25,000 shares of the Company's Common Stock at prices ranging from $0.265 per share to $0.275 per share."}],"balance_after":8257742,"source":{"system":"sec-edgar","filing":"0000950170-23-048771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023048771/ownership.xml","form_type":"4"}},{"id":1780015,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-15T16:05:11.000Z","date":"2023-09-14","kind":"purchase","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 14, 2023, Dr. Hoyoung Huh purchased a total of 20,000 shares of the Company's Common Stock at prices ranging from $0.26 per share to $0.275 per share."}],"balance_after":8232742,"source":{"system":"sec-edgar","filing":"0000950170-23-048367","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023048367/ownership.xml","form_type":"4"}},{"id":1780014,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-15T16:05:11.000Z","date":"2023-09-13","kind":"purchase","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 13, 2023, Dr. Hoyoung Huh purchased a total of 30,000 shares of the Company's Common Stock at prices ranging from $0.271 per share to $0.28 per share."}],"balance_after":8212742,"source":{"system":"sec-edgar","filing":"0000950170-23-048367","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023048367/ownership.xml","form_type":"4"}},{"id":1781944,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T16:05:03.000Z","date":"2023-09-12","kind":"purchase","planned":false,"acquired":true,"shares":17000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 12, 2023, Dr. Hoyoung Huh purchased a total of 17,000 shares of the Company's Common Stock at prices ranging from $0.275 per share to $0.28 per share."}],"balance_after":8182742,"source":{"system":"sec-edgar","filing":"0000950170-23-047919","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047919/ownership.xml","form_type":"4"}},{"id":1781943,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T16:05:03.000Z","date":"2023-09-11","kind":"purchase","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 11, 2023, Dr. Hoyoung Huh purchased a total of 30,000 shares of the Company's Common Stock at prices ranging from $0.28 per share to $0.32 per share."}],"balance_after":8165742,"source":{"system":"sec-edgar","filing":"0000950170-23-047919","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047919/ownership.xml","form_type":"4"}},{"id":1782849,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T16:05:14.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23.  None of those purchases were made."}],"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-047707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047707/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-01"}},{"id":1782848,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T16:05:14.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23.  None of those purchases were made."}],"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-047707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047707/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-01"}},{"id":1782847,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T16:05:14.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23.  None of those purchases were made."}],"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-047707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047707/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-01"}},{"id":1782846,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T16:05:14.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23.  None of those purchases were made."}],"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-047707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047707/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-01"}},{"id":1782845,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T16:05:14.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23.  None of those purchases were made."}],"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-047707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047707/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-01"}},{"id":1782844,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T16:05:14.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23.  None of those purchases were made."}],"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-047707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047707/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-01"}},{"id":1782843,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T16:05:14.000Z","date":"2023-08-29","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On September 1, 2023, a representative of Hoyoung Huh mistakenly reported purchases of 93,250 shares of the Company's Common Stock between 08/29/23 and 08/31/23.  None of those purchases were made."}],"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-047707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023047707/ownership.xml","form_type":"4/A","original_submission_date":"2023-09-01"}},{"id":1790754,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T16:05:39.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"shares":13000,"price":0.265,"value":3445.0,"ownership":{"direct":true},"balance_after":8228992,"source":{"system":"sec-edgar","filing":"0000950170-23-046053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023046053/ownership.xml","form_type":"4"}},{"id":1790753,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T16:05:39.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":56100,"price":0.255,"value":14305.5,"ownership":{"direct":true},"balance_after":8215992,"source":{"system":"sec-edgar","filing":"0000950170-23-046053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023046053/ownership.xml","form_type":"4"}},{"id":1790752,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T16:05:39.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":11400,"price":0.265,"value":3021.0,"ownership":{"direct":true},"balance_after":8159892,"source":{"system":"sec-edgar","filing":"0000950170-23-046053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023046053/ownership.xml","form_type":"4"}},{"id":1790751,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T16:05:39.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":3750,"price":0.251,"value":941.25,"ownership":{"direct":true},"balance_after":8148492,"source":{"system":"sec-edgar","filing":"0000950170-23-046053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023046053/ownership.xml","form_type":"4"}},{"id":1790750,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T16:05:39.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":0.26,"value":650.0,"ownership":{"direct":true},"balance_after":8144742,"source":{"system":"sec-edgar","filing":"0000950170-23-046053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023046053/ownership.xml","form_type":"4"}},{"id":1790749,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T16:05:39.000Z","date":"2023-08-30","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":0.253,"value":253.0,"ownership":{"direct":true},"balance_after":8142242,"source":{"system":"sec-edgar","filing":"0000950170-23-046053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023046053/ownership.xml","form_type":"4"}},{"id":1790748,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-01T16:05:39.000Z","date":"2023-08-29","kind":"purchase","planned":false,"acquired":true,"shares":5500,"price":0.25,"value":1375.0,"ownership":{"direct":true},"balance_after":8141242,"source":{"system":"sec-edgar","filing":"0000950170-23-046053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023046053/ownership.xml","form_type":"4"}},{"id":1807254,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Purchase)","published_at":"2023-08-15T16:33:50.000Z","date":"2023-08-14","kind":"other","planned":false,"acquired":false,"shares":583333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":176292,"derivative":{"exercise_price":0.6,"exercise_date":"2023-04-28","expiration_date":"2028-04-28","underlying":"Common Stock","underlying_shares":583333},"source":{"system":"sec-edgar","filing":"0000950170-23-042830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023042830/ownership.xml","form_type":"4"}},{"id":1807253,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-15T16:33:50.000Z","date":"2023-08-14","kind":"other","planned":false,"acquired":true,"shares":583333,"price":0.6,"value":349999.8,"ownership":{"direct":true},"balance_after":8135742,"source":{"system":"sec-edgar","filing":"0000950170-23-042830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023042830/ownership.xml","form_type":"4"}},{"id":1824752,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Purchase)","published_at":"2023-07-21T16:30:27.000Z","date":"2023-07-20","kind":"other","planned":false,"acquired":false,"shares":458333,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":759625,"derivative":{"exercise_price":0.6,"exercise_date":"2023-04-28","expiration_date":"2028-04-28","underlying":"Common Stock","underlying_shares":458333},"source":{"system":"sec-edgar","filing":"0000950170-23-033840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023033840/ownership.xml","form_type":"4"}},{"id":1824751,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-21T16:30:27.000Z","date":"2023-07-20","kind":"other","planned":false,"acquired":true,"shares":458333,"price":0.6,"value":274999.8,"ownership":{"direct":true},"balance_after":7552409,"source":{"system":"sec-edgar","filing":"0000950170-23-033840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000095017023033840/ownership.xml","form_type":"4"}},{"id":1843397,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Purchase)","published_at":"2023-06-27T17:00:17.000Z","date":"2023-06-23","kind":"other","planned":false,"acquired":false,"shares":666667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1217958,"derivative":{"exercise_price":0.6,"exercise_date":"2023-04-28","expiration_date":"2028-04-28","underlying":"Common Stock","underlying_shares":666667},"source":{"system":"sec-edgar","filing":"0000899243-23-016550","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924323016550/doc4.xml","form_type":"4"}},{"id":1843396,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-27T17:00:17.000Z","date":"2023-06-23","kind":"other","planned":false,"acquired":true,"shares":666667,"price":0.6,"value":400000.2,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Due to an administrative error in the Reporting Person's previous Form 4, the number of shares beneficially owned is being corrected in this Form 4 to match the Reporting Person's Schedule 13D filed on March 21, 2023."}],"balance_after":7094076,"source":{"system":"sec-edgar","filing":"0000899243-23-016550","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924323016550/doc4.xml","form_type":"4"}},{"id":1862084,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T17:16:59.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":14000,"derivative":{"exercise_price":23.09,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-23-035531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000120919123035531/doc4.xml","form_type":"4"}},{"id":1908121,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Notes","published_at":"2023-05-02T16:30:18.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"price":1130775,"reported_value":1130775,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Convertible Notes accrue interest at 6.0% per annum. At any time prior to maturity, the Reporting Person may convert the unpaid principal amount of the Convertible Notes, together with any accrued but unpaid interest, into shares of the Company's common stock at a price per share equal to $0.60. The Convertible Notes mature on October 28, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Convertible Notes accrue interest at 6.0% per annum. At any time prior to maturity, the Reporting Person may convert the unpaid principal amount of the Convertible Notes, together with any accrued but unpaid interest, into shares of the Company's common stock at a price per share equal to $0.60. The Convertible Notes mature on October 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The Convertible Notes accrue interest at 6.0% per annum. At any time prior to maturity, the Reporting Person may convert the unpaid principal amount of the Convertible Notes, together with any accrued but unpaid interest, into shares of the Company's common stock at a price per share equal to $0.60. The Convertible Notes mature on October 28, 2023."}],"derivative":{"expiration_date":"2023-10-28","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0000899243-23-011994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924323011994/doc4.xml","form_type":"4"}},{"id":1908120,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Purchase)","published_at":"2023-05-02T16:30:18.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":1884625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The warrants and convertible promissory notes (the \"Convertible Notes\") were received in consideration for the conversion of outstanding loans by Dr. Huh to the Issuer."}],"balance_after":1884625,"derivative":{"exercise_price":0.6,"exercise_date":"2023-04-28","expiration_date":"2028-04-28","underlying":"Common Stock","underlying_shares":1884625},"source":{"system":"sec-edgar","filing":"0000899243-23-011994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924323011994/doc4.xml","form_type":"4"}},{"id":2125366,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-03T21:50:37.000Z","date":"2022-11-01","kind":"other","acquired":true,"shares":372562,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea, and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Hannol Ventures LLC (the \"LLC\"). The Reporting Person is sole member of the LLC."}],"balance_after":372652,"source":{"system":"sec-edgar","filing":"0000899243-22-035081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924322035081/doc4.xml","form_type":"4"}},{"id":2125365,"issuer":{"id":85431,"kind":"organization","name":"Peak Bio, Inc.","symbol":"PKBO"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-03T21:50:37.000Z","date":"2022-11-01","kind":"other","acquired":true,"shares":6442438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea, and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea."}],"balance_after":6422438,"source":{"system":"sec-edgar","filing":"0000899243-22-035081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924322035081/doc4.xml","form_type":"4"}},{"id":2225261,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T16:21:22.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters beginning October 1st and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 16, 2022 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting."}],"balance_after":15000,"derivative":{"exercise_price":6.8,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013199","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000156761922013199/doc1.xml","form_type":"4"}},{"id":2649669,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T20:47:49.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":13286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting."}],"balance_after":13286,"derivative":{"exercise_price":28.2,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":13286},"source":{"system":"sec-edgar","filing":"0001209191-21-044178","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000120919121044178/doc4.xml","form_type":"4"}},{"id":3116124,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-06-09T21:21:17.000Z","date":"2020-06-05","kind":"exercise","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by pH Pharma Co., Ltd. (\"pH Pharma\"). The Reporting Person has a majority ownership in pH Pharma and also has voting power over the shares. The Reporting Person disclaims beneficial ownership of the shares held by pH Pharma, except to the extent of his proportionate pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":139860},"source":{"system":"sec-edgar","filing":"0000899243-20-015879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924320015879/doc4.xml","form_type":"4"}},{"id":3116123,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T21:21:17.000Z","date":"2020-06-05","kind":"exercise","acquired":true,"shares":139860,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by pH Pharma Co., Ltd. (\"pH Pharma\"). The Reporting Person has a majority ownership in pH Pharma and also has voting power over the shares. The Reporting Person disclaims beneficial ownership of the shares held by pH Pharma, except to the extent of his proportionate pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":239619,"source":{"system":"sec-edgar","filing":"0000899243-20-015879","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924320015879/doc4.xml","form_type":"4"}},{"id":3885218,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-22T18:55:33.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":83720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 83,720 stock options (the \"Grant\") on June 22, 2018 (the \"Grant Date\").  The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date"}],"balance_after":83750,"derivative":{"exercise_price":17,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":83720},"source":{"system":"sec-edgar","filing":"0000899243-18-017777","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924318017777/doc4.xml","form_type":"4"}},{"id":3892321,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-15T17:51:36.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":14000,"derivative":{"exercise_price":25.25,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-18-016823","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000089924318016823/doc4.xml","form_type":"4"}},{"id":3929294,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-17T20:42:56.000Z","date":"2018-05-15","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates."}],"balance_after":70000,"derivative":{"exercise_price":3.43,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000886744-18-000033","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674418000033/edgar.xml","form_type":"4"}},{"id":4118126,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-02T23:13:49.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":10764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 29, 2017 of $1.80 per share."}],"balance_after":154301,"source":{"system":"sec-edgar","filing":"0000886744-18-000001","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674418000001/edgar.xml","form_type":"4"}},{"id":4198366,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-02T21:25:24.000Z","date":"2017-09-29","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 29, 2017 of $2.18 per share."}],"balance_after":143537,"source":{"system":"sec-edgar","filing":"0000886744-17-000041","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674417000041/edgar.xml","form_type":"4"}},{"id":4269654,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-30T23:44:34.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":6995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2017 of $2.77 per share."}],"balance_after":134649,"source":{"system":"sec-edgar","filing":"0000886744-17-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674417000035/edgar.xml","form_type":"4"}},{"id":4274450,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-22T13:58:58.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":14000,"derivative":{"exercise_price":13.78,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001140361-17-025790","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000114036117025790/doc1.xml","form_type":"4"}},{"id":4327208,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-11T00:51:27.000Z","date":"2017-05-09","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates."}],"balance_after":50000,"derivative":{"exercise_price":2.63,"expiration_date":"2027-05-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000886744-17-000028","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674417000028/edgar.xml","form_type":"4"}},{"id":4367441,"issuer":{"id":4989,"kind":"organization","name":"GERON CORP"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-31T23:35:21.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":8535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 31, 2017 of $2.27 per share."}],"balance_after":127654,"source":{"system":"sec-edgar","filing":"0000886744-17-000018","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886744/000088674417000018/edgar.xml","form_type":"4"}},{"id":4488093,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":38676,"kind":"person","name":"Huh Hoyoung","position":1,"cik":"0001401267","reported_name":"Huh Hoyoung","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, Scientific Adv. Bd."}}],"security":"Stock Option (right to buy)","published_at":"2017-01-18T15:28:35.000Z","date":"2016-10-31","kind":"grant","acquired":true,"shares":4000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in forty-eight equal installments beginning on the date so indicated and every month thereafter, such grant vested in full at 4 years."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On October 31, 2016, the Reporting Person was granted 8,500,000 shares of common stock. Pursuant to Board approval and a Refresh Option Agreement, the number of shares was reduced for no consideration on December 27, 2016. An additional 2,700,000 shares may be issued upon certain performance only criteria."}],"balance_after":4000000,"derivative":{"exercise_price":1.2,"expiration_date":"2026-10-31","underlying":"Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0001140361-17-002117","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401267/000114036117002117/doc1.xml","form_type":"4"}}]}